Preferred epitope peptide of novel coronavirus nucleocapsid protein as well as coding gene and application thereof
By screening and verifying the preferred epitope peptide of SARS-CoV-2 nucleocapsid protein, combined with MHC-I molecular analysis, a novel epitope vaccine was developed, which solved the problem of low immune response in the prior art and achieved high Reactive and broad-spectrum immune effects.
Patent Information
- Application Number
- CN202411228991.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-22
AI Technical Summary
In the prior art, the immune response to the nucleocapsid protein of the novel coronavirus (SARS-CoV-2) is low, and lacks a highly reactive preferred epitope peptide, making it difficult to effectively activate the immune response and cover different variants.
Through prediction and verification by a variety of bioinformatics tools, the preferred epitope peptide of SARS-CoV-2 nucleocapsid protein with high affinity, strong immunogenicity, and conserved interspecies within the species were screened, and the MHC-I molecule was combined for in-depth analysis. , develop novel epitope vaccines to improve immune response and stability.
Achieve a high-responsive immune response to SARS-CoV-2, enhance the cross-expressive immune response to different variants, improve the stability and broad spectrum of vaccines, reduce adverse reactions, and is suitable for vaccine applications in a wide range of populations. .
Smart Images

Figure CN118994307A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of microbial immunotechnology, and specifically relates to preferred epitope peptides of novel coronavirus nucleocapsid proteins, their encoding genes and applications. Background Art
[0002] The novel coronavirus (SARS-CoV-2) is the pathogen of severe acute respiratory syndrome, which causes extremely high infection and mortality rates. There are many proteins on the surface of the virus, among which the SARS-CoV-2 nucleocapsid (NP) protein plays an important role in the coronavirus life cycle and participates in various important activities after the virus invades.
[0003] Major histocompatibility complex (MHC) class I restricted cluster of differentiation 8 (CD8 + )T cell response is an important antiviral immune response, and the recognition of viral peptides plays an important role in antiviral infection. Only peptides with high affinity and tight binding to MHC-I molecules can reach the cell surface and further trigger an immune response. Therefore, the immunogenicity of epitopes is indispensable for elucidating antiviral immunity. At the same time, the conservation of antigens also plays an important role in the interaction between pathogens and hosts and the establishment of herd immunity. The existence of evolutionary conserved epitopes is crucial for the survival of the virus, so vaccines developed based on conserved epitopes may provide long-term and lasting protection against the virus regardless of its strain.
[0004] Recently, epitope-based vaccine development strategies have become an alternative to traditional vaccine design and immunotherapy. Epitope-based vaccines have many advantages over traditional vaccine development. They can not only improve safety by reducing adverse reactions, but also cover a wide range of people and ultimately improve vaccine efficiency. Currently, there are few known SARS-CoV-2NP antigen peptides that can effectively activate the body's immune response, and the immune response reactivity is low. Therefore, it is urgent to screen and identify new preferred epitope peptides of SARS-CoV-2NP protein with high immune response reactivity. Summary of the invention
[0005] In view of the above technical problems, one of the purposes of the present invention is to provide a preferred epitope peptide of the new coronavirus nucleocapsid protein, the amino acid sequence of the preferred epitope peptide is shown in any one of SEQ ID NO.1 to 8, and the preferred epitope peptide has the characteristics of high affinity, strong immunogenicity, conservation between species and within species, good binding to MHC-I molecules, and high reactivity of T cell immune response. Applying the preferred epitope peptide of the present invention to the development of epitope vaccines will improve the stability of the epitope vaccine effect and may also induce cross-immune reactions between different variants.
[0006] A second object of the present invention is to provide a gene encoding the preferred epitope peptide.
[0007] The third object of the present invention is to provide the use of the preferred epitope peptide in the preparation of anti-new coronavirus products.
[0008] The fourth purpose of the present invention is to provide the application of the gene in the preparation of anti-new coronavirus products.
[0009] Furthermore, in the above application, the product is a vaccine.
[0010] The fifth object of the present invention is to provide a novel coronavirus epitope vaccine, the immunogen of which comes from a combination of one or more of the preferred epitope peptides.
[0011] Furthermore, the vaccine also includes a pharmaceutically acceptable carrier.
[0012] Furthermore, the vaccine may or may not contain an adjuvant.
[0013] Compared with the prior art, the present invention has the following beneficial effects:
[0014] The present invention predicts and verifies potential epitopes derived from SARS-CoV-2NP through ElISpot assays. And conducts multiple in-depth analyses of the protective properties of different variants around the world. We further predict the binding affinity of these epitopes to the appropriate sites of the respective MHC-I molecules and their immunogenicity, which will ultimately help understand the immunobiology of SARS-CoV-2NP and improve the design of epitope vaccines against the virus in the future. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 The number of high-affinity preferred epitopes for SARS-CoV-2 NP of human HLA-I subtypes was predicted by five prediction tools.
[0016] Figure 2 The number of high-affinity preferred epitopes of mouse H-2 subtype against SARS-CoV-2 NP was predicted by five prediction tools.
[0017] Figure 3 This is a two-level clustering analysis of all predicted 9 peptides of SARS-CoV-2NP. The direction indicated by the arrows indicates the affinity from strong to weak.
[0018] Figure 4 This is a statistical chart of the inter-species and intra-species conservation of human HLA-I class molecules and mouse H-2 molecules.
[0019] Figure 5 It is a docking model for the optimal epitope and MHC-I class molecule.
[0020] Figure 6 To express the preferred epitope CD8+ ELISpot test results of T cell immune response reactivity.
[0021] Figure 7 This is the WebLogo image of the high-frequency mutation site.
[0022] Figure 8 These are the 4 high-frequency mutations and their mutation frequencies.
[0023] Fig. 9 This is a heat map of the epitope involved in the mutation site before and after mutation.
[0024] Fig.10 This is a scatter plot of the differences between the epitopes involved in the mutation site before and after mutation. DETAILED DESCRIPTION
[0025] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0026] Example 1
[0027] Obtaining the preferred epitope peptide of the new coronavirus nucleocapsid protein
[0028] 1: Amino acid sequence search:
[0029] The 2019-nCoV nucleocapsid protein (NP, gene number: NC_045512.2[28274..29533]) was obtained from the NCBI GenBank database as input for various bioinformatics tools for epitope prediction, conservation analysis, molecular docking, and experiments.
[0030] 2: Epitope prediction:
[0031] For mouse H2-Db, HA-Dd, H2-Kb, H2-Kd, H2-Kk and H2-Ld epitope prediction, several database methods such as IEDB method (http: / / tools.iedb.org / mhci / ), SMMPMBEC from the immune epitope database (http: / / tools.immuneepitope.org / mhci / ), NetMHCpan 4.1 (http: / / www.cbs.dtu.dk / services / NetMHCpan / ), SYFPEITHI (http: / / www.syfpeithi.de / bin / MHCServer.dll / EpitopePrediction.htm) and Rankpep (http: / / imed.med.ucm.es / Tools / rankpep.html) were used for prediction. The predicted epitopes that accounted for the top 2% of the total predicted epitopes were selected. Finally, when data sources existed in all five databases, epitopes predicted by at least three prediction tools were selected for subsequent in-depth analysis; when data were retrieved from only four databases, epitopes predicted by at least two prediction tools were selected for subsequent in-depth analysis.
[0032] Human major leukocyte antigen HLA-I supertype allele epitopes, [HLA-A1 (A0101, A2601, A3001, and A3002), HLA-A2 (A0201, A0203, A0206, and A6802), HLA-A3 (A0301, A1101, A3001, A3101, A3301, and A6801), HLA-A24 (A2301, A2402), HLA-A3201, HL A-B7 (B0702, B3501, B5101, and B5301), HLA-B8 (B0801), HLA-B15 (B1501), HLA-B44 (B4001, B4402, and B4403), and HLA-B58 (B5701 and B5801), HLA-B46 (HLA-B4601), HLA-C0401]., cumulative coverage of more than 97% of the population was predicted using the same tools described above. Ultimately, all top 2% epitopes of the respective supertypes predicted by these tools were selected and further investigated.
[0033] For mouse MHC-I subtypes, epitopes predicted by at least three prediction tools were selected when data sources existed in all five databases; when data were retrieved from only four databases, epitopes predicted by at least two prediction tools were selected. For human HLA-I subtypes, all 9 peptides that appeared in the top 2% of the prediction results were considered preferred epitopes. As described above, bioinformatics analysis was performed using multiple computational tools to predict potential MHC-I epitopes with different binding affinities across SARS-CoV-2 nucleocapsid proteins. Mouse (H2-Db, HA-Dd, H2-Kb, H2-Kd, H2-Kk, and H2-Ld) and major HLA-I supertype alleles were analyzed. Figure 1 and Figure 2 The number of preferred epitopes generated by each prediction tool is listed. After recalculating and excluding repeated 9 peptides, we obtained 64 high-affinity epitopes in the H-2 subtype and 238 high-affinity epitopes in the HLA-I subtype. In the mouse H-2 subtype, H-2-Db has the largest number of high-affinity epitopes, which is 19 9 peptides. In the human HLA-I subtype, HLA-A3 has the largest number of preferred epitopes, which is 48 9 peptides.
[0034] 3: Peptide synthesis:
[0035] The corresponding peptides were synthesized according to the predicted peptide sequence. All 9 peptides used in the experiment were completed by Shanghai Qiangyao Biotechnology Co., Ltd. with a purity of 95%, totaling 1 mg. After centrifugation of the synthesized peptide powder, 20 μL of dimethyl sulfoxide (DMSO) was added to dissolve it, and then 480 μL of sterile ddH2O was added to mix well and frozen in a -20°C refrigerator for later use.
[0036] 4: Computer analysis:
[0037] (1) 9-peptide clustering analysis: In order to study the uptake and processing capabilities of different HLA class I superfamilies for SARS-CoV-2NP 9-peptide peptides, and whether there are similarities between MHC molecules of different individuals or even different species in processing SARS-CoV-2NP 9-peptide peptides, we performed a two-level clustering analysis on 411 SARS-CoV-2NP peptides. Figure 3The differences between different MHC-I subtypes were shown. The 36 MHC-I class molecules were divided into three groups, including HLA-I subtype group, cross-subtype group and H-2 subtype group. In the HLA-I group, HLA-A3001 and HLA-A3 (-A0301, -A1101, -A3101) scored similarly, and HLA-A1 (-A3002), HLA-B15 (-B1501), and HLA-A3201 also obtained similar scores; HLA-A3 (-A3301, -A6801), HLA-A1 (-2601) also obtained similar results. In the cross-reaction group, there were obvious regional differences. HLA-A2 (-A0201, -A0203, -A0206, and -A6802) scored similarly to H2-Db and H2-Kb; HLA-B44 (B4001, B4402, and B4403) scored more similarly to H2-Kk; HLA-B7 (-B3501, -B5101, and -B5301) scored similarly to H2-Ld. In the H-2 group, only H-2Dd had no similarity to other MHC molecules.
[0038] (2) Immunogenicity analysis: A nine-peptide peptide that simply exhibits high affinity with MHC class I molecules may not induce a sufficient immune response. It must have high immunogenicity while having high immunoreactivity. The immunogenicity of the peptide itself is determined by its amino acid sequence. We used IEDB-recommended (http: / / tools.iedb.org / mhcii / , accessed on 6August 2021) to detect whether the nine-peptide peptide is immunogenic. A score > 0 is considered to be immunogenic. In our experimental results, 177 out of 411 SARS-CoV-2NP nine-peptides were judged to be immunogenic. Specifically, 43 nine-peptides were immunogenic among 107 HLA-I subtype high-affinity epitopes, and 20 nine-peptides were immunogenic among 42 H-2 subtype preferred epitopes.
[0039] (3) Conservation analysis: In order to determine the conservation of predicted epitopes between protein sequences of different SARS-CoV-2 strains, we used the BLASTP tool to perform inter-species and intra-species conservation analysis of all selected preferred predicted epitopes of the new coronavirus. The intra-species conservation evaluation standard is SARS-related coronavirus (taxid: 694009), excluding SARSacute respiratory syndrome coronavirus2 (taxid: 2697049). The inter-species conservation evaluation standard is Betacoronavirus (taxid: 694002), excluding SARS-related coronavirus (taxid: 694009). In the analysis results, if the E value <e -5 , then the peptide is considered to be conserved. The preferred epitopes can be divided into four categories according to the conservation status: conserved within species but not conserved between species, conserved within species but intermediately conserved, not conserved within species but conserved between species, and not conserved within species but not conserved between species. According to the conservation analysis of pan-MHC class I restricted epitopes, Figure 4 The statistical results of the conservation analysis of all preferred epitopes are listed. Among them, there are two peptides that are conserved both within and between species. Finally, we combined the affinity, immunogenicity, conservation of all 9 peptides of SARS-CoV-2NP and the range of MHC genotypes to which they are affinitized, and obtained 8 preferred epitopes (amino acid sequences as shown in SEQ ID NO.1 to 8) for further molecular docking and other immunological studies. The names and sequences of the 8 preferred epitopes are as follows:
[0040] 9mer_SARS2-NP_48 (SEQ ID NO. 1): NTASWFTAL.
[0041] 9mer_SARS2-NP_104 (SEQ ID NO. 2): LSPRWYFYY.
[0042] 9mer_SARS2-NP_105 (SEQ ID NO. 3): SPRWYFYYL.
[0043] 9mer_SARS2-NP_153 (SEQ ID NO. 4): NNAAIVLQL.
[0044] 9mer_SARS2-NP_216 (SEQ ID NO. 5): DAALALLLL.
[0045] 9mer_SARS2-NP_219 (SEQ ID NO. 6): LALLLLDRL.
[0046] 9mer_SARS2-NP_299 (SEQ ID NO. 7): KHWPQIAQF.
[0047] 9mer_SARS2-NP_331 (SEQ ID NO. 8): LTYTGAIKL.
[0048] The statistical results of the analysis of pan-MHC class I preferred epitopes were as follows: Figure 4 It can be seen that the pan-HLA-I restricted preferred epitopes are more conserved than the H-2 restricted preferred epitopes. This is because the results in HLA-I summarize the superfamily in many alleles, while the identification of H-2 restricted epitopes requires approval of 3 / 5 algorithms. At the same time, the preferred epitopes show that inter-species conservation is significantly stronger than intra-species conservation.
[0049] (4) Peptide-MHC molecule docking
[0050] HPEPDOCK is a new type of web server that can simulate molecular docking by inputting 9-peptide preferred epitope sequences and MHC-I class molecule RDB format files to obtain a docking model.
[0051] The RCSBPDB database (https: / / www.rcsb.org / ) can be used to obtain the relevant MHC-I class molecule 3D structure data {HLA-A1[HLA-A*0206(3OXR)], HLA-B7[HLA-B*0702(5EO1), HLA-B*3501(1A9E), HLA-B*5101(1E28), HLA-B*5301(1A1N)], HLA-B8[HLA-B*0801(4QRP)], HLA-B15[HLA-B*1501(1XR9), HLA-A*0101(4NQV)], HLA-B44[HLA-B*4402(3KPL)], H2-Ld(6L9M), H2-Kb(6JQ3), H2-Db(1JUF)}.
[0052] Among the binding modes between the 8 preferred epitopes and different MHC molecules, we mainly analyzed the top ten binding modes with the lowest binding energy. And the average binding energy of these ten binding modes was obtained. Among them, the 9-peptide epitopes LSPRWYFYY, SPRWYFYYL, and KHWPQIAQF had lower average binding energy than other epitopes during the docking process, showing good docking performance and more stable chemical thermodynamic properties, that is, the energy required to break the existing epitope structure is higher than other epitopes. This may help to infer that these three epitopes show stronger affinity and immunoreactivity than other epitopes. And this characteristic was exhibited during the docking process with human HLA-1 subtype and mouse H-2 allele. The scores of 4 epitopes in docking with human HLA-I subtype during the docking process were lower than those when docking with mouse H-2 allele, that is, they showed better docking performance; while the other 4 epitopes were more inclined to bind to mouse H-2 allele, but the score difference was small. The docking model, such as Figure 5 shown.
[0053] When these epitopes were confirmed to induce good cellular immune responses in BALB / c and C57BL / 6 mice in mouse ELISpot experiments, it was speculated that they may play a broad role in inducing cellular immune responses in humans.
[0054] 5: ELISpot assay verification
[0055] The cellular immune response to the NP epitope was assessed by interleukin (IL)-2 ELISpot assay according to the manufacturer's protocol (BD Pharmingen, Franklin Lakes, New Jersey, USA). Specifically, the IL-2-specific capture antibody was diluted with 5 μg / mL (1:250) sterile PBS and placed on the coated ELISpot plate at 4°C overnight. The mice were sacrificed, their spleens were dissected, and the mononuclear cell suspension was ground. After erythrocyte lysis, the spleen cells were rinsed and resuspended. After blocking the ELISpot plate with RPMI-1640 containing 10% fetal bovine serum at room temperature for 2 hours, 1×10 6splenocytes and stimulated with synthetic NP peptides at a final concentration of 25 μg / mL. The plates were incubated in a 5% CO2 incubator at 37°C for 24 h. Complete medium was used as a negative control. Con A (10 μg / mL) was used as a positive control. After incubation, the plates were washed with H2O and PBST and then incubated with 2 mg / mL of the relevant biotinylated anti-mouse IL-2 antibody at room temperature for 2 h. After washing with PBST (0.05% Tween20), the plates were incubated with 1:100 streptavidin-horseradish peroxidase (streptavidin-HRP) for 1 h, 3-amino-9-ethylcarbazole (AEC; DAKEWEI, Shenzheng, China) was added to the HRP substrate, and the reaction was terminated by washing with water. After air drying, we counted the IL-2 spots produced by the AEC substrate using a CTL ELISpot reader (Kennesaw, Atlanta, GA, USA). Each experiment was performed in triplicate, and all results are shown as per 10 6 The bar graph was drawn using GraphPad Prism 8.0.1.
[0056] Eight MHC-restricted 9-peptide preferred epitope peptides were artificially synthesized for ELISpot experiment verification. SARS-CoV-2 The secretion of IL-2 was observed in the spleen cells of mice immunized with plasmids. Figure 6 Displayed as every 10 6 The average of spot forming units (SFU) per spleen cell. It can be seen from the figure that the spleen cells of BALB / c and C57 mice secreted IL-2 after being stimulated by 8 9 peptides respectively. Interestingly, the amount of IL-2 secreted by C57 mouse spleen cells was greater than that of BALB / c mouse spleen cells, regardless of whether they were stimulated by H2d or H2k restricted epitopes.
[0057] Example 2: Application of preferred epitopes of SARS-CoV-2 nucleocapsid (NP) protein
[0058] The present invention lays a foundation for the research of novel genetic engineering vaccines for SARS-CoV-2NP by predicting the preferred MHC-I epitopes on SARS-CoV-2NP and various computer analyses.
[0059] 1: Sequence alignment of SARS-CoV-2NP variants
[0060] Based on SARS-CoV-2NP, we obtained the results of 85 variants ClustalX2.1 (Conway Institute UCD Dublin, Ireland). And compared them using WebLogo (http: / / weblogo.berkeley.edu / logo.cgi, accessed on 3December 2021). The height of the letters in the results represents the frequency of amino acid mutations in different variants. According to the results, we analyzed and drew a graph of the impact of a specific amino acid mutation on all related 9-peptide peptides around it. The peptides with the highest mutation frequency were selected and TBtools was used to draw a heat map of the δ values of the binding affinity of SARS-CoV-2NP with the corresponding HLA-I and 9-peptide antigen epitope variants, where a positive RANK value means that the binding affinity of SARS-CoV-2 is greater than that of the variant, and conversely, a negative RANK value means that the binding affinity of the variant is greater than that of the original strain.
[0061] Finally, we used Origin 2021 (OriginLab, Northampton, MA, USA) to draw a scatter plot of the binding affinity of the T157H mutation of the SARS-CoV-2NP nonapeptide peptide segment to the original strain, where the horizontal axis is the result of taking the logarithm of the SARS-CoV-2NP binding affinity to the base 2, and the vertical axis is the result of taking the logarithm of the variant binding affinity to the base 2.
[0062] Through the affinity heat map, we obtained 8 SARS-CoV-2NP peptides with high affinity. Based on these 8 high-affinity peptides, we compared the sequences of the SARS-CoV-2NP strain with the other 85 variants. Through the comparison results, we found 3 peptides with high frequency mutations among these 8 high-affinity peptides ( Figure 7 ), involving 6 high-frequency mutation sites ( Figure 8 ), involving 4 mutations (T157H, D217E, A218T, I336T), and the mutation frequencies were I157L 85.89%, D217E 81.18%, A218T 81.18%, I336T 12.94%.
[0063] Fig. 9The heat map shows the difference in affinity before and after the mutation of the peptide involved in the site with the highest mutation probability I157L. Among them, the original strain of SARS-CoV-2NP showed higher affinity in the binding of YTGAIKLDD to HLA-A1 and HLA-B58, while other variants showed higher affinity than the original strain in the binding of YHGAIKLDD to HLA-24. In addition, PSGTWLTYH, GTWLTYHGA, and TYHGAIKLD have higher affinity in other variants.
[0064] Fig.10 It further indicates the difference in binding between the peptides involved and the HLA-I molecules before and after the I157L mutation. The horizontal axis represents the affinity of the SARS-CoV-2NP epitope, taking the logarithm with base 2, and the vertical axis represents the affinity in the SARS-CoV-2NP variant, also taking the logarithm with base 2. Different colors represent different HLA types, and different shapes represent different mutations. Each point in the scatter plot represents a nine-peptide epitope, and the points in the gray area represent the affinity ranking of the epitope in the top 2%. The closer the point is to the straight line y=x, the closer the affinity between SARS-CoV-2NP and the variant is. As can be seen from the figure, the epitope in aa148-aa166 has the greatest difference before and after mutation. In aa148-aa166, a single site mutation changes the binding ability of SARS-CoV-2NP with four HLA-I class molecules; three of them have increased affinity with the site variant, and only one has the opposite, suggesting that the mutation of SARS-CoV-2NP has little effect on the affinity of the selected epitope, and the mutation may even promote the affinity of the epitope.
[0065] The above research found that the preferred MHC-I epitope on SARS-CoV-2NP has high affinity, immunogenicity and conservation between species and within species. At the same time, molecular docking simulated a possible docking model, which also showed good efficacy in dealing with SARS-CoV-2NP variants.
[0066] In recent years, although epitope vaccines related to SARS-CoV-2NP have been developed at home and abroad, there are still many deficiencies in terms of application, such as the interference of redundant amino acids caused by long peptide segments, and the failure to comprehensively screen epitopes based on high affinity, immunogenicity, and conservation between species and within species. The preferred MHC-I epitopes on SARS-CoV-2NP screened by the method of the present invention, if used to stimulate the body's cellular immune response, will have the following advantages:
[0067] 1. After viral infection, antigen presenting cells (APC) present antigenic peptides through MHC-I molecules to activate CD8 +T cells. For MHC-I class molecules, both ends of the antigen binding groove are blocked by conserved tyrosine residues, resulting in the size of the binding peptide being usually limited to 8-10 amino acid residues. Therefore, we selected a 9-amino acid peptide as the predicted epitope. At the same time, the cellular immune response mediated by CTL plays an important role in antiviral infection. After CTL recognizes virus-infected cells (target cells), it releases perforin, granzyme and passes through the FasL-Fas pathway, causing the target cells to lyse and die, thereby effectively clearing the virus-infected cells in the body. The level and activity of a virus-specific CTL in the body are positively correlated with the clearance effect of the virus.
[0068] 2. Neutralizing antibodies can specifically bind to viruses to prevent them from infecting host cells, but completely eliminating the virus in the body requires CD8 + T cells exert cytotoxic effects to clear intracellular infected viruses.
[0069] 3. Epitope prediction methods are used to predict the binding affinity of each 9-peptide peptide segment to a specific MHC-I class molecule. Currently, there are many different algorithms for predicting peptide affinity, so we use multiple prediction methods to predict peptides with strong binding affinity. At the same time, we performed immunogenicity analysis on all predicted 9-peptides to eliminate non-immunogenic epitopes with high affinity.
[0070] 4. Previous studies have focused more on the HLA-A*02 subtype. In the present invention, we predicted and studied 33 MHC-I class molecule genotypes, including 27 human genotypes and 6 mouse genotypes. It can be said that our preferred epitopes have a wide range of MHC-I reactivity, overcoming the differences in MHC-I molecules caused by population and regional distribution. Good immune responses can be induced among different races in different regions, which helps to obtain a broader and more effective herd immunity.
[0071] 5. After the inter-species and intra-species conservation analysis of the 9-peptide preferred epitopes for the new coronavirus, the high-affinity and high-immunogenic epitopes can be simply classified. Compared with other epitopes, the inter-species and intra-species conserved preferred epitopes are more suitable for vaccine development and immune research. Simulation docking of the inter-species and intra-species conserved preferred mouse epitopes with the corresponding mouse H-2 and human HLA-I class molecules produced good results.
[0072] 6. Sequence comparison and affinity analysis of SARS-CoV-2NP and 85 variants indicate that mutations in SARS-CoV-2NP have little effect on the affinity of the preferred epitope, and even promote the affinity of the epitope. Applying the preferred epitope to the development and application of epitope vaccines will improve the stability of the epitope vaccine effect and may induce cross-immune responses between different variants.
[0073] In the present invention, we propose a method for screening preferred selective epitopes, based on a variety of prediction tools and databases, which not only reduces the accidental errors caused by a single database, but also reduces the waste of human resources and human errors caused by repeated human experiments. The prediction results are compared with subsequent experiments, which increases the accuracy of the results. Our experiments also carried out peptide segment and MHC-I class molecule docking simulation and variation comparison, adding the understanding of cross-immunity between different types of viruses, to provide guidance for the subsequent development of epitope vaccines with a high protection range. In addition, there are also literatures proving that epitope-based vaccines can induce strong and specific immune responses against specific preferred epitopes.
[0074] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0075] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A preferred epitope peptide of a novel coronavirus nucleocapsid protein, characterized in that: The amino acid sequence of the preferred epitope peptide is shown in any one of SEQ ID NOs. 1 to 8.
2. A gene, characterized in that The gene encodes the preferred epitope peptide according to claim 1.
3. Use of the preferred epitope peptide according to claim 1 in the preparation of anti-new coronavirus products.
4. Use of the gene described in claim 2 in the preparation of anti-new coronavirus products.
5. The use according to claim 3 or claim 4, characterized in that: The product is a vaccine.
6. A novel coronavirus epitope vaccine, characterized in that: The immunogen is derived from one or more combinations of the preferred epitope peptides described in claim 1.
7. The novel coronavirus epitope vaccine according to claim 6, characterized in that: The vaccine also includes a pharmaceutically acceptable carrier.
8. The novel coronavirus epitope vaccine according to claim 6, characterized in that: The vaccine may or may not contain an adjuvant.
Citation Information
Cited By
T cell immunodominance epitope peptide of SARS-CoV-2 nucleocapsid protein mutation site and application of T cell immunodominance epitope peptide
CN120682326A
